MedTrace Logo

Individualized Systems Medicine Functional Profiling for Recurrent Glioblastoma

NCT05043701 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-04-03

No results posted yet for this study

Summary

A study to determine the feasibility and safety of individualized cancer stem cell targeted therapy based on high-throughput functional profiling of FDA/EMA-approved drugs in patients with GBM that has recurred or progressed following standards-of-care (RT, TMZ).

Conditions

Interventions

DRUG

Personalized drug combination

A personalized drug combination will be prescribed to each patient based on the functional drug screen

Sponsors & Collaborators

  • Institute for Molecular Medicine

    collaborator OTHER

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Einar O. Vik-Mo, MD, PhD · Oslo University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2024-12-31
Completion
2026-02-28

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05043701 on ClinicalTrials.gov